Skip to content

Hannah Thurgur

3 papers in the library · 23 citations · publishing 2023-2025

Papers

ARC: a framework for access, reciprocity and conduct in psychedelic therapies

Frontiers in Psychology May 11, 2023 Hannah Thurgur, Meg J. Spriggs, Ashleigh Murphy-Beiner et al. 13 citations

A framework called Access, Reciprocity and Conduct (ARC) is proposed to build an ethical and equitable infrastructure for psychedelic-assisted therapy (PAT). ARC rests on three pillars: ensuring equal access to PAT for those needing mental health treatment, promoting safety for those delivering and receiving therapy, and respecting traditional and spiritual uses of psychedelic medicines. The framework is being developed through a dual-phase co-design approach, first co-creating ethics statements with stakeholders from research, industry, therapy, community, and Indigenous settings, then inviting broader collaborative review. The authors aim to spark dialogue and help organizations and practitioners address complex ethical questions in PAT.

Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial.

Br J Clin Pharmacol January 17, 2024 Hannah Thurgur, Michael Lynskey, Anne Katrin Schlag et al. 7 citations

Lingering long COVID symptoms often severely impact daily life. A trial explored if a cannabidiol-dominant product offers a viable treatment. Participants experienced encouraging improvements in issues like pain, sleep, fatigue, and anxiety. This suggests a promising way to alleviate these symptoms and significantly boost overall quality of life for those affected by long COVID.

MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up.

Alcohol and alcoholism (Oxford, Oxfordshire) May 14, 2025 Hannah Thurgur, Ben Sessa, Laurie Higbed et al. 3 citations

In an open-label feasibility study, 14 adults with alcohol use disorder who had recently completed detoxification underwent an eight-week course of ten psychotherapy sessions, including two sessions with MDMA. Bayesian analysis estimated a 55%–63% probability of a two-level reduction in World Health Organization drinking risk three months after treatment. Preliminary findings also indicated reductions in alcohol craving and improvements in sleep and aspects of psychosocial functioning at the three-month follow-up compared to baseline. The results provide initial insights into MDMA-assisted psychotherapy's potential to improve quality of life and well-being beyond reducing drinking.